| Identification | Back Directory | [Name]
OXYCODONE HYDROCHLORIDE | [CAS]
124-90-3 | [Synonyms]
eubine
oxikon
oxycon
oxykon
Oxycod
tecodin
tekodin
eucodal
eukodal
eutagen
oxykodal
dinarkon
thecodin
thekodin
tecodine
Supeudol
Oxygesic
Combunox
OxyContin
stupenone
pancodine
thecodine
Roxicodone
OXYCODONE HCL
oxycodonhydrochloride
percodanhydrochloride
dihydronehydrochloride
OXYCODONE HYDROCHLORIDE
OXYCODONEHYDROCHLORIDE,USP
25333-72-6 (Terephthalate)
Oxycodone Hydrochloride (CII)
Oxycodon HCL(injection grade)
dihydroxycodeinonehydrochloride
dihydrooxycodeinonehydrochloride
oxycodone hydrochloride solution
Oxycodone Hydrochloride CII (1 g)
Oxycodone Hydrochloride (CII), USP
14-hydroxydihydrocodeinonehydrochloride
Dihydro-14-hydroxycodeinone hydrochloride
OXYCODONE HYDROCHLORIDE*METHANOL SOLUTIO N
OXYCODONE HYDROCHLORIDE NARCOTIC ANALGES IC
oxycodone hydrochloride--dea schedule*ii item
Codeinone, 7,8-dihydro-14-hydroxy-, hydrochloride (6CI, 7CI)
4,5a-Epoxy-14-hydroxy-3-methoxy-N-methyl-6-oxomorphinan hydrochloride
(5α)-4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-onehydrochloride
4,5-alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-morphinan-6-onhydrochloride
4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-morphinan-6-one,hydrochloride,(5-a
(5a)-4,5-Epoxy-14-hydroxy-3-methoxy-17-methyl-morphinan-6-one Hydrochloride
Morphinan-6-one, 4,5a-epoxy-14-hydroxy-3-methoxy-17-methyl-, hydrochloride (8CI)
Morphinan-6-one,4,5-epoxy-14-hydroxy-3-Methoxy-17-Methyl-, hydrochloride (1:1), (5a)-
Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, hydrochloride, (5a)- (9CI)
4,5-Epoxy-14-hydroxy-3-methoxy-17-methyl-morphinan-6-one, hydrochloride, (5-alpha)- (9ci) | [EINECS(EC#)]
204-717-1 | [Molecular Formula]
C18H22ClNO4 | [MDL Number]
MFCD00137583 | [MOL File]
124-90-3.mol | [Molecular Weight]
351.82 |
| Chemical Properties | Back Directory | [Appearance]
White Solid | [Melting point ]
261-2630C | [alpha ]
D20 -125° (c = 2.5) | [Fp ]
11℃ | [storage temp. ]
2-8°C
| [solubility ]
Freely soluble in water, sparingly soluble in anhydrous ethanol, practically insoluble in toluene. | [form ]
neat | [Water Solubility ]
142.9g/L(temperature not stated) | [CAS DataBase Reference]
124-90-3 |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Uses]
Controlled substance (opiate). Analgesic (narcotic) | [Biological Activity]
Potent and selective μ -opioid receptor agonist (K i values are 16 and >1000 nM for hMOR1 and hKOR1 respectively). | [Description]
Oxycodone (hydrochloride) (Item No. 26513) is an analytical reference standard categorized as an opioid.1 Oxycodone is regulated as a Schedule II compound in the United States. This product is intended for research and forensic applications. | [Originator]
Oxyfast,Purdue Pharma, L.P. | [Definition]
ChEBI: Oxycodone hydrochloride is a hydrochloride obtained by reaction of oxycodone with one molar equivalent of hydrochloric acid. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain. It has a role as a mu-opioid receptor agonist, an antitussive and an opioid analgesic. It contains an oxycodone(1+). | [Brand name]
Oxycontin (Purdue); Roxicodone (Roxane); Roxicodone (Xanodyne). | [Therapeutic Function]
Narcotic analgesic | [Clinical Use]
Oxycodone is about equipotent with morphine, but because of the 3-OCH group, it has a much
lower oral:parenteral dose ratio. Thus, oxycodone is used orally to treat severe to moderate pain. It
is a drug as a single agent and when combined in strong analgesic mixtures.
Oxycodone has a plasma half-life of approximately 4 hours and requires dosing every 4 to 6 hours. | [Drug interactions]
Potentially hazardous interactions with other drugs
Analgesics: possible opioid withdrawal with
buprenorphine and pentazocine.
Antibacterials: metabolism possibly increased by
rifampicin; metabolism inhibited by telithromycin.
Antidepressants: CNS excitation or depression
with MAOIs - avoid; possible CNS excitation or
depression with moclobemide; increased sedative
effects with tricyclics.
Antifungals: concentration increased by voriconazole.
Antihistamines: increased sedative effects with
sedating antihistamines.
Antipsychotics: enhanced hypotensive and sedative
effects.
Antivirals: concentration possibly increased by
ritonavir.
Dopaminergics: avoid with selegiline.
Nalmefene: avoid concomitant use.
Sodium oxybate: enhanced effect of sodium oxybate
- avoid. | [Metabolism]
Oxycodone is metabolised in the liver to produce
noroxycodone via the CYP3A system, oxymorphone via
the CYP2D6 system and various conjugated glucuronides.
The analgesic effects of the metabolites are clinically
insignificant. Both metabolites undergo glucuronidation
and are excreted with unchanged drug in urine. |
| Safety Data | Back Directory | [Hazard Codes ]
Xn,T,F | [Risk Statements ]
22-39/23/24/25-23/24/25-11 | [Safety Statements ]
36/37-45-16-7 | [RIDADR ]
UN 1230 3/PG 2
| [WGK Germany ]
3
| [RTECS ]
QD2470000
| [HazardClass ]
6.1(a) | [PackingGroup ]
II | [HS Code ]
2939110000 | [Toxicity]
cat,LDLo,intravenous,2500ug/kg (2.5mg/kg),LUNGS, THORAX, OR RESPIRATION: OTHER CHANGESBEHAVIORAL: ANALGESIA,Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 194, Pg. 296, 1940. |
|